AIM ImmunoTech Announces Closing of its Rights Offering

Rhea-AI Summary

AIM ImmunoTech (NYSE:AIM) announced the closing of its rights offering on March 6, 2026, which generated approximately $1.8 million in total subscriptions. Each purchased Unit was priced at $1,000 and consisted of one share of Series G convertible preferred stock and 2,000 Class G warrants.

The offering used a Form S-1 registration (No. 333-292085) declared effective by the SEC on February 10, 2026, with a prospectus supplement filed February 27, 2026. Maxim Group acted as dealer-manager.

Positive

• Completed capital raise of approximately $1.8 million
• Each Unit sold at a defined $1,000 subscription price
• Transaction processed under an effective Form S-1 registration

Negative

• Each Unit includes 2,000 Class G warrants, creating potential share dilution
• Issuance of Series G convertible preferred stock may affect capital structure and future conversions

Key Figures

Rights offering proceeds: $1.8 million Unit subscription price: $1,000 per Unit Preferred stock per Unit: 1 share Series G +2 more

5 metrics

Rights offering proceeds $1.8 million Total subscriptions in closed rights offering

Unit subscription price $1,000 per Unit Rights offering subscription price

Preferred stock per Unit 1 share Series G Convertible preferred included in each Unit

Warrants per Unit 2,000 Class G warrants Common stock purchase warrants in each Unit

Shelf registration size $100 million Maximum aggregate amount under S-3 shelf

Market Reality Check

Price: $0.6944 Vol: Volume 318,307 is below t...

low vol

$0.6944 Last Close

Volume Volume 318,307 is below the 20-day average of 581,988, suggesting a muted pre-news setup. low

Technical Shares at $0.6944 are trading below the 200-day MA of $2.69 and far under the 52-week high of $20.33.

Peers on Argus

AIM gained about 8.33% while tracked biotech peers were mixed, with moves rangin...

1 Up 1 Down

AIM gained about 8.33% while tracked biotech peers were mixed, with moves ranging from about -9.7% to +15.6%. Momentum scanner peers also split between up and down, supporting a stock-specific reaction rather than a sector-wide move.

Previous Offering Reports

5 past events · Latest: Mar 04 (Negative)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 04	Rights offering results	Negative	-1.3%	Preliminary rights offering results with estimated $1.8M in subscriptions.
Feb 25	Offering extension	Negative	-4.7%	Extension of subscription period for ongoing rights offering.
Feb 12	Offering correction terms	Negative	+58.2%	Corrected commencement terms for rights offering with up to $12M proceeds.
Feb 11	Offering commencement	Negative	-13.5%	Launch of rights offering to sell up to 12,000 Units.
Jan 27	Offering terms change	Negative	+0.8%	Amended key dates and terms, keeping up to $12M targeted proceeds.

Pattern Detected

Offering-related headlines often saw negative price reactions, with one notable positive outlier on initial commencement terms.

Recent Company History

Over recent months, AIM has repeatedly updated investors on a rights offering structure, from initial commencement on Feb 11, 2026 through amended terms and extended subscription periods, targeting up to $12.0 million in proceeds. Price reactions to these offering updates were mostly negative or modestly positive. The current announcement of the offering’s closing for about $1.8 million fits into this capital-raising sequence following earlier preliminary results disclosed on Mar 4, 2026, and continues the theme of dilution-focused news alongside ongoing clinical efforts.

Historical Comparison

+7.9% avg move · Past offering headlines for AIM produced average moves of about 7.91%, with mostly negative reaction...

offering

+7.9%

Average Historical Move offering

Past offering headlines for AIM produced average moves of about 7.91%, with mostly negative reactions and one large upside outlier, framing today’s rights-offering closing within a volatile capital-raise history.

Offering news progressed from amended terms and commencement, through extensions and revised economics, to preliminary results and now closing of the rights offering.

Regulatory & Risk Context

Active S-3 Shelf · $100 million

Shelf Active

Active S-3 Shelf Registration 2025-06-27

$100 million registered capacity

AIM has an effective S-3 shelf filed on 2025-06-27, authorizing up to $100 million of various securities. This provides flexibility to raise additional capital via common or preferred stock, debt, warrants, or units through future prospectus supplements, which could introduce further dilution depending on structure and size.

Market Pulse Summary

This announcement confirms the closing of AIM’s rights offering, generating about $1.8 million throu...

Analysis

This announcement confirms the closing of AIM’s rights offering, generating about $1.8 million through Units of Series G convertible preferred stock and 2,000 warrants per Unit. It caps a sequence of offering-related updates that previously drove mixed but often negative price reactions. Investors tracking the story may focus on how this funding complements the company’s existing $100 million shelf registration and whether additional capital raises follow, alongside progress in Ampligen clinical programs and any changes to balance-sheet strength.

Key Terms

rights offering, convertible preferred stock, warrants, registration statement on Form S-1, +2 more

6 terms

rights offering financial

"announced today the closing of its previously announced rights offering"

A rights offering is a way for a company to raise additional money by giving existing shareholders the opportunity to buy more shares at a discounted price before they are offered to the public. It’s similar to a special sale where current owners get the first chance to buy extra items at a lower cost, allowing them to increase their investment if they choose. This process matters to investors because it can affect the value of their holdings and their ability to buy new shares at favorable terms.

convertible preferred stock financial

"consisting of one share of the Company’s Series G Convertible Preferred Stock"

Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.

warrants financial

"and 2,000 Class G Common Stock Purchase Warrants to purchase the Company’s Common Stock"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

registration statement on Form S-1 regulatory

"The Company’s registration statement on Form S-1 (Registration No. 333-292085)"

A registration statement on Form S-1 is a detailed filing a company submits to the U.S. securities regulator to register new shares for public sale; it includes a plain-language prospectus, financial statements, business description and risk factors. For investors it matters because it provides the official, comprehensive blueprint of the offering — like an owner’s manual — allowing buyers to assess risks, inspect financial health and compare valuation before deciding to invest.

prospectus supplement regulatory

"as modified by the prospectus supplement filed with the SEC on February 27, 2026"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

dealer-manager financial

"Maxim Group LLC acted as dealer-manager for the Rights Offering"

A dealer-manager is the lead broker or firm that organizes and runs a securities offering, coordinating other dealers, setting up the sale, marketing the issue to investors, and handling order allocation and settlement. Think of it as the project manager for a new issue: its effectiveness affects how widely the offering is distributed, the fees charged, and how smoothly investors can buy or sell the securities, so investors watch the dealer-manager for potential conflicts, pricing quality, and execution reliability.

AI-generated analysis. Not financial advice.

OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – announced today the closing of its previously announced rights offering (the “Rights Offering”). The Rights Offering resulted in total subscriptions of approximately $1.8 million.

Each right entitled the holder to purchase one unit (“Unit”), at a subscription price of $1,000 per Unit, consisting of one share of the Company’s Series G Convertible Preferred Stock (the “Preferred Stock”), and 2,000 Class G Common Stock Purchase Warrants to purchase the Company’s Common Stock (the “Warrants”).

Maxim Group LLC acted as dealer-manager for the Rights Offering.

The Company’s registration statement on Form S-1 (Registration No. 333-292085) was declared effective by the Securities and Exchange Commission (“SEC”) on February 10, 2026, as modified by the prospectus supplement filed with the SEC on February 27, 2026. The prospectus relating to and describing the terms of the Rights Offering has been filed with the SEC as a part of the registration statement and is available on the SEC's website at https://www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About AIM ImmunoTech

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

Forward Looking Statements

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in the press release speak only as of the date of the press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The Company is in various stages of seeking to determine whether Ampligen® will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders and disclosures in the Company’s reports filed with the SEC on its website and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Among the studies are clinical trials that provide only preliminary data with a small number of subjects, and no assurance can be given that the findings in these studies will prove true or that the study or studies will yield favorable results. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

Please review the “Risk Factors” section in the Company’s latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and the registration statement. Its filings are available at www.aimimmuno.com. The information found on the Company’s website is not incorporated by reference herein and is included for reference purposes only.

IR Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

FAQ

How much capital did AIM (NYSE:AIM) raise in the March 2026 rights offering?

AIM raised approximately $1.8 million in total subscriptions. According to the company, the amount reflects the aggregate subscriptions received through the completed rights offering on March 6, 2026.

What did one Unit in AIM's (AIM) rights offering include and what was the price?

Each Unit cost $1,000 and included one Series G convertible preferred share and 2,000 Class G warrants. According to the company, that composition defined the subscription terms for each exercised right.

Will AIM's (NYSE:AIM) rights offering cause dilution for existing shareholders?

The rights offering may increase potential dilution because each Unit includes 2,000 warrants. According to the company, the warrants provide future purchase rights that could expand the share count if exercised.

Which filings and approvals covered AIM's (AIM) rights offering in 2026?

The offering was made under a Form S-1 (No. 333-292085) declared effective by the SEC on February 10, 2026, with a prospectus supplement filed February 27, 2026. According to the company, those filings describe offering terms.

Who managed AIM's (AIM) rights offering and where can investors find the prospectus?

Maxim Group acted as dealer-manager for the rights offering. According to the company, the prospectus is filed with the SEC and available on the SEC website for investor review.